Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Articles

Explore innovative nonsteroidal treatments for atopic dermatitis, as experts discuss personalized care strategies to enhance patient quality of life.

3 Cases, 3 Triumphs: Rethinking AD Management

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Shannon C. Trotter, DO, FAOCD, FAAD, and patient Janene Tirado, highlight GPP Awareness Day and the urgent need for recognition and understanding of generalized pustular psoriasis.

Q&A: Celebrating the First Annual GPP Awareness Day

TikTok's vitiligo content reveals a critical need for reliable clinical information from HCPs, highlighting the gap between engagement and accuracy in health education.

The Most Popular Vitiligo Content on TikTok Lacks Medical Accuracy

Merck's pembrolizumab gains Health Canada approval for innovative perioperative treatment of advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Pembrolizumab Becomes First Approved Perioperative Immunotherapy for Resectable HNSCC in Canada

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Washington - Tighter restrictions on Accutane could have a reverse effect - increased black market activity - the FDA told a congressional investigative subcommittee on Dec. 11.

Accutane Illicitly Sold, Congress, FDA Warn

Columbus - When it comes to the regulation of office-based surgery, Brett Coldiron, M.D., has plenty to beef about in the Buckeye State. He even has a popular rally cry:

Lipo Rules Bad to the ...

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

' Weekly Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

This week's special edition of the Dermatology Times crossword focuses on he recent approval of delgocitinib for adults with moderate to severe CHE who have not responded adequately to prior topical corticosteroids or for whom corticosteroid use is not advisable.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Top country involved in the DELTA trials besides the US.

Delgocitinib inhibits how many JAK isoforms?

This clinical trial assessed long-term safety and efficacy of delgocitinib.

This condition is characterized by relapsing or persistent hand eczema for more than 3 months.

This dermatologist called delgocitinib “a first-in-class topical therapy poised to simplify our approach to CHE.”

Brand name of delgocitinib cream approved for CHE in 2025.

According to Gooderham et al. 2025, what was the most common non-infectious adverse event reported during DELTA 3?

This JAK inhibitor is the first topical treatment FDA-approved for CHE.

Patients with which two IGA-CHE scores were not treated during DELTA 3 unless relapse occurred? (Answer format: “__ or __”)

The severity of CHE was assessed using this index.

First region outside the US where delgocitinib was approved.

Delgocitinib cream is applied how many times per day?

The 2025 medical meeting where post hoc data on delgocitinib was presented.

This symptom, alongside pain, was significantly reduced by delgocitinib.

This metric measured treatment success in the DELTA trials.

Delgocitinib, a JAK inhibitor, has been approved for adults with moderate to severe chronic hand eczema (CHE) who have not adequately responded to topical corticosteroids or cannot use them. The DELTA trials, including DELTA 3, assessed its long-term safety and efficacy. Delgocitinib inhibits multiple JAK isoforms and is the first FDA-approved topical treatment for CHE. The brand name for the cream will be released in 2025. The treatment significantly reduces symptoms like itching and pain, with the most common non-infectious adverse event being dermatitis.

Test your knowledge of key words and terms associated with the recent approval of delgocitinib for adults with moderate to severe CHE.

Quizzes

Dermatology Times' Weekly Crossword: August 10, 2025

To stay informed with the latest conference insights,

2025 Society for Pediatric Dermatology (SPD) Annual Meeting 

wrapped up with a strong emphasis on innovation, global perspectives, and community updates, offering attendees both clinical pearls and future-forward tools to bring back to their practices.

The morning kicked off with updates from the American Board of Dermatology and Pediatric Dermatology subspecialty leadership. Julie Schaffer, MD, and Andrea Zaenglein, MD, provided attendees with the latest information on board certification, evolving practice standards, and how the specialty continues to grow in response to changing health care needs.

This was followed by a brief awards presentation, recognizing outstanding contributions in research, service, and mentorship across the field.

Continuing a popular tradition throughout the meeting, Luke Johnson, MD, returned for a third installment of Hot Topics & Trends in Pediatric Dermatology, delivering a snapshot of the latest developments in diagnostics, therapies, and care delivery models.

One of the standout sessions of the day was the second installment of the Hurwitz Lecture, where Angela Hernandez Martin, MD, returned to the podium to present Pediatric Dermatology Reimagined: The Game-Changing Tool of Ultrasound. With practical insights and case examples, Hernandez Martin outlined how high-frequency ultrasound is transforming diagnostic accuracy and non-invasive monitoring in pediatric patients, particularly in complex skin and soft tissue conditions.

Eichenfield Urges Lifelong Learning Amid Evolving Treatment Landscape

The morning continued with 2 focused talks. Molly Youssef, MD, of the Mayo Clinic, explored the often-overlooked realm of mucosal disease in pediatric populations, offering guidance on early recognition and multidisciplinary management. James Bennett, MD, PhD, followed with a discussion on the application of genetic testing in vascular anomalies clinics, highlighting how genomic advances are leading to more targeted diagnoses and personalized treatment pathways.

Following a mid-morning break and poster viewing session, the program resumed with a series of brief but impactful updates. Carrie Coughlin, MD, MPHS, shared highlights from the latest PeDRA (Pediatric Dermatology Research Alliance) meeting, emphasizing collaborative research priorities and funding opportunities. James Treat, MD, then offered a snapshot of discussions from the recent World Congress of Pediatric Dermatology, underscoring global initiatives and cross-border partnerships in improving pediatric skin health.

As the meeting began to wind down, Solveig Ophaug, MD, and Rachel Dunlap, MD, delivered the Pediatric Dermatology Year in Review, synthesizing key studies, therapeutic advancements, and practice-changing evidence published over the past year.

Finally, SPD closed its 2025 meeting with part 2 of Sam Weinberg’s Cases of the Year, an attendee favorite. As in previous sessions, expert faculty presented unusual or diagnostically challenging cases that sparked lively discussion and illustrated the importance of curiosity, collaboration, and clinical rigor in pediatric dermatology.

With 3 days of robust programming, powerful tributes, and dynamic conversations, SPD 2025 concluded on a high note—equipping clinicians with the tools, insights, and connections needed to shape the future of the specialty.

keep up to date with the latest in coverage from the conference

The 2025 Society for Pediatric Dermatology Annual Meeting concluded with a focus on innovation, global perspectives, and community updates. Key sessions included updates on board certification, evolving practice standards, and the use of high-frequency ultrasound in diagnostics. Presentations covered mucosal disease management, genetic testing in vascular anomalies, and collaborative research priorities. The meeting highlighted global initiatives and partnerships, and concluded with a review of significant studies and challenging cases. Attendees left equipped with new tools, insights, and connections to advance pediatric dermatology.

Catch up on coverage from the third day of the 50th Annual Society for Pediatric Dermatology Meeting in Seattle, Washington.

Day 3 Recap: 50th Annual SPD Dermatology Conference 2025

offered a rich blend of celebration, education, and reflection, as attendees honored trailblazers in the field while examining evolving clinical, research, and practice-based themes.

The sessions opened with the presentation of the AAP Alvin Jacobs Award, recognizing Lawrence Schachner, MD, for his distinguished contributions to pediatric dermatology. Teresa Wright, MD, presented the award, highlighting Schachner’s legacy in both patient care and mentorship. This was followed by brief announcements and another round of Hot Topics & Trends in Pediatric Dermatology from Luke Johnson, MD.

Lawrence Schachner, MD, Reflects on Career, Mentorship, and Innovation

Next, Ginna Sybert, MD, was inducted into the SPD Hall of Fame, presented by Melinda Jen, MD. Sybert was honored for her impact on the field through clinical genetics and mentorship.

The morning’s clinical centerpiece was the Cases in Search of a Diagnosis Panel, where a powerhouse lineup of experts—including Ilona Frieden, MD, and Antonio Torrelo, MD—walked attendees through complex patient scenarios with elusive or evolving diagnoses. The collaborative session showcased the value of group wisdom in unraveling diagnostic mysteries.

Following this, Dawn Siegel, MD, provided updates from the SPD Year in Review, including highlights from the compensation survey results, giving members data-driven insights into workforce trends.

A highlight of the morning was a special session marking SPD’s 50th anniversary, framed through the legacy of the late Robert Sidbury, MD. Moderated by Markus Boos, MD, and Heather Brandling-Bennett, MD, the panel brought together leaders such as Amy Paller, MD, and Peter Lio, MD, to reflect on Sidbury’s contributions and the broader evolution of pediatric dermatology. The conversation offered a moving tribute and an inspiring vision for the future of the specialty.

Robert Sidbury, MD, MPH, Leaves a Lasting Legacy in Pediatric Care

Following time for poster viewing, the program resumed with 3 targeted lectures. Jennifer Huang, MD, outlined what pediatric dermatologists need to know about Graft-Versus-Host Disease, while Harper Price, MD, presented on the management of congenital melanocytic nevi. Sarah Coates, MD, then delivered a thoughtful talk on the impact of social determinants of health in clinical dermatology, challenging attendees to consider systemic influences on care and outcomes.

The Research Panel, featuring Cory Simpson, MD, PhD, Keith Choate, MD, PhD, and Anna Cristina Garza-Mayers, MD, PhD, rounded out the morning with updates on novel investigations and translational science in dermatology.

The afternoon wrapped up with breakout sessions tailored to diverse interests and career stages. Topics ranged from practical tips for inbox management and EHR efficiency (led by Mimi Cabrera, MD) to resilient communication, leadership strategies for section chiefs, and a social media workshop titled In the Spotlight: Mastering Media, Messaging, and Social Media. An Advanced Practice Provider-focused session on biologics and targeted therapies, led by Aditi Murthy, MD, also underscored SPD’s commitment to inclusive, multidisciplinary education.

Lisa Swanson, MD, FAAD, Highlights Expanding Pediatric Treatment Options

With a focus on both honoring the past and preparing for the future, Friday’s sessions reinforced SPD 2025’s central themes: community, clinical excellence, and forward-thinking innovation.

Day 2 of the 2025 Society for Pediatric Dermatology Annual Meeting celebrated leaders in pediatric dermatology while exploring clinical, research, and practice-based themes. Lawrence Schachner, MD, received the AAP Alvin Jacobs Award, and Ginna Sybert, MD, was inducted into the SPD Hall of Fame. The event featured a diagnostic panel, updates on workforce trends, and a tribute to Robert Sidbury, MD. Sessions covered topics like Graft-Versus-Host Disease, congenital melanocytic nevi, and social determinants of health, concluding with breakout sessions on diverse professional interests.

Catch up on coverage from the second day of the 50th Annual Society for Pediatric Dermatology Meeting in Seattle, Washington.

Day 2 Recap: 50th Annual SPD Dermatology Conference 2025

Pruritic, purple, polygonal, planar papules and plaques

Pink coloured plaques with silvery scales

The management of lung cancer brain metastases has seen significant advancements, with a focus on personalized treatment strategies. The integration of targeted therapies and immunotherapies has improved patient outcomes, offering more effective and less invasive options compared to traditional methods. Stereotactic radiosurgery and whole-brain radiation therapy remain crucial, but their roles are evolving with the advent of novel systemic therapies. Multidisciplinary approaches are essential for optimizing treatment plans, considering factors such as genetic mutations, patient performance status, and potential side effects. Ongoing research continues to refine these strategies, aiming for improved survival and quality of life.

Polls 

POLL: How Does Lichen Planus Present Clinically?

Robert Sidbury, MD, MPH, a prominent figure in pediatric dermatology, died unexpectedly on Friday, July 11, 2025. Dr Sidbury, 61, was the chief of dermatology at Seattle Children’s Hospital and a professor in the University of Washington’s Department of Pediatrics. His death has deeply saddened the dermatology community, including those in the Society for Pediatric Dermatology (SPD), the American Academy of Dermatology, and the Pediatric Dermatology Research Alliance, where he was a proud member and leader.

The SPD held a special tribute to honor Dr Sidbury’s life and contributions at its 

, titled “The Society for Pediatric Dermatology at 50: A View of Our Specialty Through the Life and Work of Dr Robert Sidbury.” Speakers at the event highlighted his profound impact as a clinician, researcher, mentor, and friend.

Dr Sidbury’s colleagues and friends remember him for his exceptional qualities. Peter Lio, MD, recalled a trip to a hydrotherapy center in the south of France with Dr Sidbury and other clinicians, where they brought patients with severe atopic dermatitis. At the SPD hosted tribute, Lio remarked, “Although it was a business trip, and we were working to learn about the treatments while trying to help and support our patients, Rob’s warmth, inquisitiveness, and incredibly sharp sense of humor made it so much more than that. We had a wonderful experience getting to know our patients better, getting to know the other dermatologists in the group, and truly enjoying the journey.” He added, “Rob was the kind of person who could make a gray Monday morning in an office feel like hanging out on a weekend. His kindness, compassion, and genuine love and interest in the world at large made everything a little bit brighter, more interesting, and more fun. He was someone with tremendous charisma, and his light will be greatly missed.”

Nanette Silverberg, MD, who was a fellow with Dr Sidbury at Children’s Memorial Hospital of Northwestern University (now the Ann & Robert H. Lurie Children’s Hospital of Chicago), described him as “always a true gentleman physician, very kind, polite, inclusive of many opinions, and generous with his time with friends, patients, and in public service.” She lauded his brilliance and humility, noting, “His conceptual work in the guidelines for atopic dermatitis created the scaffold for the adoption of new, cutting-edge therapeutics and improved the lives of countless children with atopic dermatitis.” Silverberg concluded, “I am saddened by his loss. He will be deeply missed within our society and by his colleagues and friends. He is irreplaceable.”

Raj Chovatiya, MD, PhD, MSCI, shared his connection: “I had the privilege of first meeting Robert when I was a dermatology resident. I was lucky to work with him as my assigned faculty mentor as a part of the DermMentors Resident of Distinction award program, which was taking place in Seattle that year. I won the top prize that year with him by my side, and that little bit of serendipity connecting us blossomed into a long-term relationship. Robert was such a kind, caring, and accomplished individual, and I was blessed to call him a colleague and a friend. He will be missed by all of us in dermatology.”

Dawn Eichenfield, MD, PhD, echoed similar sentiments, recalling her first encounter with Dr Sidbury at the Resident of Distinction event in Seattle. “Although he was not my assigned ‘mentor’ for the event, he was so kind and welcoming, and the experience left such a memorable impression that it helped confirm my decision to become a pediatric dermatologist.”

Amy Paller, MD, MS, recounted Dr Sidbury’s fellowship at Lurie Children’s Hospital in Chicago and his move to Seattle 25 years ago to begin his faculty career. She remembered him as “a pleasure to be with, funny, a great listener, and with great common sense. He was always curious and had a great love of learning, taking a few years to earn a master’s degree in public health and investigating the relationship between vitamin D levels and atopic dermatitis.” Paller emphasized Dr Sidbury’s role as “a champion in teaching about the management and triggers of atopic dermatitis, cochairing the American Academy of Dermatology’s guidelines committee twice.” She concluded, “Above all, he was incredibly giving to his trainees, his colleagues, and his patients. We are all shocked and saddened by this sudden loss of our dear friend and colleague, and we offer our heartfelt sympathy to his wife, daughter, and all who knew and loved him.”

Dr Sidbury’s impact extended beyond his professional achievements. He was known for his dedication to his daughter, Claire, and his love for his wife, Sheila. He built the Division of Pediatric Dermatology at Seattle Children’s Hospital into a strong, tight-knit, vibrant team. He fostered an environment where everyone felt valued and supported, creating “brave spaces” where colleagues could be their authentic selves. His ability to connect with people, his dry humor, and his unwavering kindness left an indelible mark on all who knew him.

Dr. Robert Sidbury, a leading figure in pediatric dermatology, passed away unexpectedly at 61. As chief of dermatology at Seattle Children’s Hospital and a professor at the University of Washington, he was celebrated for his contributions to the field, particularly in atopic dermatitis. Colleagues and friends remember him for his warmth, humor, and mentorship. His work significantly impacted clinical guidelines and patient care, and he was deeply involved in professional societies. Dr. Sidbury's legacy includes his dedication to family, fostering supportive environments, and his profound influence on peers and patients.

The pediatric dermatology community mourns the loss of Dr Robert Sidbury, a beloved leader and mentor, celebrated for his compassion and groundbreaking contributions.

Thomas P. Skernivitz

Articles

Latest Updated Articles